Skip to main content

Table 7 Antitumor activity and body weight change of TH-302 in combination with AZD7762 in the HT29 xenograft model

From: Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

 

TH-302 Intermittent Regimen

TH-302 Intermittent Regimen

TH-302 Daily Regimen

 

TH-302 100 mg/kg, AZD 20 mg/kg,

TH-302 100 mg/kg, AZD 12.5 mg/kg,

TH-302 50 mg/kg, AZD 12.5 mg/kg,

 

TGI

TGD1000

MT

ILS

MBL

TGI

TGD1000

MBL

MT

ILS

TGI

TGD1000

MBL

MT

ILS

 

(%)

(days)

(days)

(%)

(%)

(%)

(days)

(%)

(day)

(%)

(%)

(days)

(%)

(days)

(%)

Vehicle

  

36

 

0

  

0

36

   

0.1

35

 

AZD7762

7.7

2

42

15

0

16

3

0

37

28

34

5

0

38

8.6

TH-302

19

4

35

-2.8

0

19

4

0

35

-2.8

38

7

0

38

8.6

ATA

67*,a,b

21

55*,a

53

1.3

54*,a,b

11

1.8

45*,a

25

-

-

-

-

-

TAA

48*,a,b

10

44*

22

5.8

54*,a,b

13

6.1

52

43

-

-

-

-

-

TA

-

-

-

-

-

-

-

-

-

-

74*a,b

16

0.7

45*

29

  1. TGI, tumor growth inhibition.
  2. TGD1000, tumor growth delay to 1000 mm3.
  3. MBL, maximal body weight loss due to drug treatment as compared with the first day of treatment.
  4. MT: Median Time to reach the size of 1000 mm3.
  5. ILS: Increased Life Span.
  6. *p <0.05 vs. vehicle group.
  7. ap <0.05 vs. AZD7762 group.
  8. bp <0.05 vs. TH-302 group.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us